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Abstract 
Fibroblast growth factor-binding protein 1 (FGFBP1, FGF-BP) is a secreted chaperone 
that mobilizes paracrine-acting FGFs, stored in the extracellular matrix, and presents 
them to their cognate receptors. FGFBP1 enhances FGF signaling including angiogenesis 
during cancer progression, and is upregulated in various cancers. Here we evaluated the 
contribution of endogenous FGFBP1 to development and homeostasis as well as to skin 
pathologies utilizing Fgfbp1-knockout (KO) mice. Relative to wild-type (WT) littermates 
KO mice showed no gross pathologies. Still, in KO mice a significant thickening of the 
epidermis associated with a decreased transepidermal water loss and increased pro-
inflammatory gene expression in the skin was detected. Also, skin carcinogen challenge 
by DMBA/TPA resulted in delayed and reduced papillomatosis in KO mice. This was 
paralleled by delayed healing of skin wounds and reduced angiogenic sprouting in 
subcutaneous matrigel plugs. Heterozygous GFP-knock-in mice revealed rapid induction 
of gene expression during papilloma induction and during wound healing.  Examination 
of WT skin grafted onto Fgfbp1 GFP knockin reporter hosts and bone marrow transplants 
from the GFP reporter model into WT hosts revealed that circulating Fgfbp1-expressing 
cells migrate into healing wounds. We conclude that tissue-resident and circulating 
Fgfbp1-expressing cells modulate skin carcinogenesis and inflammation.  
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Introduction 
The fibroblast growth factor binding protein (FGFBP) family consists of three human and 
two murine (FGFBP1, 3) members, which are secreted chaperone proteins that bind to 
FGFs and enhance their biological activity (Tassi and Wellstein 2006). As the best 
characterized member, FGFBP1 has been shown to bind to FGF1, 2, 7, 10 and 22 in a 
reversible manner through its C-terminal domain (Tassi et al. 2011). Paracrine FGFs (e. 
g. FGF1 and FGF2) are immobilized in the extracellular matrix and are released to bind 
to their cognate FGF receptors. In this context FGFBP1 works as a modulator that 
chaperones the FGFs from their location in the extracellular matrix to target cells 
expressing FGF receptors. 
FGFBP1 is expressed in epithelial cells in skin, stomach, eye, ileum and colon (Aigner et 
al. 2002; Kurtz et al. 1997), was found to act as an angiogenic switch molecule in cancer 
(Czubayko et al. 1997) and expressed in squamous cell carcinoma (Czubayko et al. 
1994), pancreatic and colon cancer (Henke et al. 2006). Also, FGFBP1 is upregulated 
during a two-step chemical skin carcinogenesis challenge with DMBA and TPA (Kurtz et 
al. 2004). We have previously investigated the role of FGFBP1 in a transgenic mouse 
model and found that conditionally expressed FGFBP1 accelerated angiogenesis in 
subcutaneously implanted matrigel plugs, enhanced wound healing and reduced ischemic 
hindlimb injury. Furthermore, FGFBP1 and FGFBP2 play a critical role during chicken 
development: knockdown of either of them caused embryonic lethality in part through 
vascular leakage. (Gibby et al. 2009).  
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To investigate the function of endogenous FGFBP1 we generated a knockout and a 
knock-in GFP-reporter mouse model, to investigate the role of FGFBP1 in development, 
skin homeostasis and repair and during challenge by chemical carcinogenesis. 
 
Results 
Generation of Fgfbp1-knockout mice 
The complete Fgfbp1 open-reading-frame contained in exon 2 on chromosome 5 was 
replaced by a floxed Fgfbp1 gene and a neo-GFP cassette, resulting in Fgfbp1+/loxP-neo-gfp 
mice, which were then crossed with mice expressing cre (Fig. 1a). The resulting mouse 
line expressed GFP in lieu of Fgfbp1 (Fgfbp1+/gfp) and served to monitor activity of the 
Fgfbp1 promoter. To generate Fgfbp1-knockout mice (KO) the Fgfbp1loxP-neo-gfp mice 
were crossed with mice expressing the recombinase Flpase and then with cre-expressing 
mice (Fig. 1b-f). The mouse strain in this study is primarily C57Bl/6N and to a lower 
degree SV129N. 
 
The epidermis of KO mice is thicker and has a reduced permeability  
Since endogenous FGFBP1 is predominantly expressed in skin (Aigner et al. 2002), we 
initially focused on the analysis of the skin phenotype in the KO animals. The epidermis 
of adult (2-3 months old) but not juvenile KO mice (3 weeks old) showed a twofold 
increased thickness (p<0.05; Fig. 2a, S1a). In contrast, the thickness of dermis, fat and 
panniculus muscle were not significantly different between WT and KO (Fig. 2b). The 
increased thickness in KO mice coincided with an increased proliferation index in basal 
keratinocytes (Fig 2c, e). Also, ~50% of the epidermis in KO mice showed multiple 
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nucleated keratinocyte strata in contrast with a mostly single basal layer in WT (Fig. 2d). 
Commensurate with epidermal thickening in KO mice transepidermal water loss (TEWL) 
was decreased (Fig. 2f). Also, global expression analysis of skin RNA, indicates 
significantly altered pathways related to barrier function in KO versus WT mice (Fig. 
S2a) although staining for Claudin1 and Filaggrin showed no differences in the epidermis 
between WT and KO (Fig. 2e). Analysis of RNA from the epidermis and from the dermis 
showed a higher expression of the macrophage marker F4/80 and Ffgr1c in the epidermis 
of KO mice (Fig. 2g). In KO mice both Fgfr1b and c are expressed at similar levels in the 
dermis and epidermis, whilst a 10-fold higher expression of the c-isoform was seen in the 
dermis vs the epidermis of WT animals (Fig. 2g). Fgf7 and Fgfr2 were not differentially 
expressed in the epidermis or dermis (Fig. S1b).  
 
FGFBP1 upregulation in patients’ psoriatic lesions and squamous cell skin cancer 
(SCC) 
Epidermal thickening observed in the Fgfbp1-KO model has been described in 
inflammatory pathologies of the skin such as psoriasis (Stern 1997) and FGFR2 and 
FGF7 were found elevated in psoriatic skin (Guban et al. 2016). To assess FGFBP1 gene 
expression we analyzed two previously published gene expression studies (Nair et al. 
2009; Reischl et al. 2007) of paired samples of normal skin, psoriatic skin without and 
with lesions. FGFBP1 is significantly upregulated in lesions but not in unaffected skin 
(Fig. S3a, b). Analysis of another study (Nindl et al. 2006) revealed that FGFBP1 is 
upregulated in actinic keratosis (AK) and invasive SCC relative to normal skin (Fig. 
S3c).  
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Skin epidermis of KO mice shows elevated pro-inflammatory gene expression 
A psoriatic phenotype can be mimicked in mice by topical application of Aldara, a pro-
inflammatory agent (Walter et al. 2013) Fig. 3a). Aldara contains Imiquimod and 
activates the innate immune system via TLR-7 on neutrophils, macrophages and dendritic 
cells and indirectly induces proliferation of keratinocytes (van der Fits et al. 2009). As a 
readout for activation by Aldara, we monitored Myeloperoxidase (MPO) activity, which 
increased during Aldara treatment in both WT and KO skin (Fig. 3b). In response to 
Aldara, the expression of Fgfbp1 increased in WT mice (2.5-fold; Fig. 3c) as did GFP 
activity in heterozygous GFP-reporter mice (Fgfbp1+/gfp; 6-fold; Fig. 3d, e). Aldara 
treatment also induced a striking, 4.5-fold epidermal thickening (Fig. 3f, g) and 
expression of the inflammatory genes Il6 and Il17a as well as the epithelial marker Krt16 
(Fig. 3h, S5a). The expression of these genes was significantly elevated at baseline in the 
skin of KO mice, indicating a skin phenotype with activated immune response and thus 
increased epithelial proliferation (Fig. 2b, d, 3f, g). It has been shown that the skin barrier 
function is highly dependent on FGF receptor expression (Yang et al. 2010). Fgfr1,2, 3, 4 
expression however, were not altered significantly in total skin (Fig. S4). These data 
suggest that the loss of Fgfbp1 induces a baseline increase in pro-inflammatory gene 
expression in KO skin comparable to the Aldara treatment effect in WT.  
 
DMBA/TPA-induced skin papilloma formation is reduced and delayed in KO mice 
Fgfbp1 expression is increased in mouse skin during carcinogen-induced papilloma 
formation (Kurtz et al. 2004) suggesting a potential role during carcinogenesis. Six week 
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old GFP reporter mice (Fgfbp1+/gfp) treated topically with DMBA/TPA (Fig. 4a) showed 
macroscopically visible GFP activity in papillomas (Fig. 4b), GFP protein expression in 
the more differentiated outer keratinocyte layers of the epidermis (Fig. 4c, magnified in 
Fig. S5b) and >2-fold GFP mRNA (Fig. 4d). In WT skin Fgfbp1 expression was induced 
similarly by 2.8-fold (Fig. 4k). Skin biopsies taken from carcinogen treated WT and KO 
mice showed a similar increase in hyperplastic keratinocyte layers as early as 12 days 
after the first treatment and maximal thickness at 57 days (Fig. 4e). However, the 
appearance of skin papillomas was significantly (p<0.01) delayed in KO mice: The first 
lesions in WT mice were found after 1.5 months (day 44) and only a month later (day 73) 
in the KO group (Fig. 4f, g). By day 100 all WT mice developed papilloma whereas one 
KO mouse remained papilloma-free until the end of the experiment (Fig. 4g). Also, the 
number of papilloma per mouse was significantly reduced in the KO mice (Fig. 4h).  
In addition to the reduced papilloma formation, we observed an increase of ulceration in 
the neck region of KO mice (Fig. S6a). In earlier work, we had observed an impact of 
FGFBP proteins on vascular leakiness in embryonic tissues (Gibby et al. 2009) and it is 
known that altered vascular permeability can cause ulcerative inflammation (Nagy et al. 
2008). Thus, we evaluated papilloma tissues for vessel integrity. Quite strikingly, the 
number of extravasated erythrocytes was increased >3-fold in the KO mice indicating a 
contribution of Fgfbp1 to vascular integrity in adult tissues (Fig. 4 i, j).  
 
Pathway activation after DMBA/TPA challenges 
To complement the phenotypic analyses, we compared the impact of DMBA/TPA 
treatment on the gene expression profile in skin and found robust gene expression 
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difference associated with epidermal development, immune response and extracellular 
matrix (ECM) (Fig. S7). Carcinogen treatment induced the activated keratinocyte-
specific genes Krt16 and Sprr2d to comparable levels in both WT and KO skin. Due to 
the elevated level at baseline, the relative induction by carcinogen was much lower in KO 
versus WT skin. The same pattern was observed for the immune response gene S100a8. 
Its baseline level expression in untreated KO skin was 13-fold higher than the expression 
in WT skin and the induction by carcinogen treatment elevated its expression to similar 
levels in both KO and WT. Finally, the ECM protease Klk6 was upregulated at baseline 
by 4.3-fold in KO skin. DMBA/TPA treatment induced its expression in both WT and 
KO skin (Fig. 4k). Immunohistochemistry confirmed the upregulation of the Krt13 and 
Krt16 protein in the epidermis as well as the downregulation of Col1A2 in the dermis 
during DMBA/TPA treatment (Fig. S5c).  
An analysis of Fgfr mRNA by qRT-PCR did not show any significant differences in b/c 
splice isoform expression of Fgfr1, 2 and 3 (Fig. S6b, c). Also, immunohistochemistry 
did not reveal any difference in keratinocyte proliferation between WT and KO (Fig. S5c, 
d). Pathway analysis of the global gene expression patterns revealed that carcinogen 
treatment activated Tight Junction Signaling, Agranulocyte Adhesion, Extravasation and 
Diapedesis, Epithelial Adherens Junction Signaling, and Role of IL-17a in Psoriasis in 
both WT and KO skin. These pathways are already activated at baseline in the untreated 
KO skin (Fig. S2a, b, c). Upstream regulators that are significantly altered with a z-score 
above 2 include Tnf, LPS, Ifn-γ, Nfκb, Cebp-α, Tgf-β1, all of which are involved in 
cancer pathways as well as inflammatory responses (Fig. S2d, e). 
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Fgfbp1 expression is induced and required for timely wound healing  
We have previously found that conditional transgenic FGFBP1 expression accelerates 
wound healing (Tassi et al. 2011). Complementary to that we observed a significant 
three-day delay in full-thickness skin wound healing in KO mice (Fig. 5a, b). This 
supports a significant contribution of endogenous Fgfbp1 to timely wound healing. 
Fgfbp1+/gfp-reporter mice showed maximal levels of GFP fluorescence adjacent to the 
wounds on day 4 (Fig. 5c, d). This was corroborated by IHC that showed a high 
expression of GFP protein close to the wounds and a low expression at remote skin (Fig. 
S8a). Fgfbp1-expressing cells were identified as hyperpoliferating keratinocytes and 
inflammatory cells in the granulation tissue (Fig. 5e magnified in Fig. S8b). Microscopic 
analysis of wounds on day four (Fig. 5f, magnified in Fig. S8c) showed that the 
reëpithelialization of wounds in the WT mice was more advanced (Fig. 5g). Also, the 
granulation tissue in wounds in KO mice contained a significantly higher number of 
extravasated erythrocytes and fewer microvessels and capillaries than WT mice (Fig. 5h,i 
magnified in Fig. S8c) indicating less mature angiogenesis. There was a slight decrease 
in total cells in the granulation tissue of KO mice (Fig S8d) though no difference in their 
proliferation index (Fig. S8e, f).  
 
Fgfbp1-expressing cells are recruited to healing wounds 
To investigate the expression of Fgfbp1 in cells recruited to healing wounds versus tissue 
resident cells we transplanted skin from WT donors onto the back of Fgfbp1+/gfp recipient 
mice. The transplanted skin was wounded and the fluorescence of the wound and the 
surrounding transplant tissue was monitored (Fig. 6a). The inside of wounds in wild type 
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skin transplanted to Fgfbp1+/gfp recipient mice started to fluoresce during wound healing 
even when surrounded by the non-fluorescent WT skin transplant (Fig. 6b, c) suggesting 
that GFP-expressing cells from the host entered the wound as early as two days after 
wounding. IHC analysis of the granulation tissue in the wound confirmed the influx of 
GFP-positive cells from the host (Fig. 6b), thus corroborating that as late as five days 
after injury Fgfbp1-expressing cells localize to the wound.  
In complementary experiments, Fgfbp1+/gfp skin transplanted and wounded on a WT 
recipient showed increased GFP activity at edge of a wound as it healed but the GFP 
activity inside the open wound did not increase significantly (Fig. S9a-d). These results 
suggest the contribution of circulating cells from the host to the wound healing of the 
transplant and we thus tested that next in a separate experimental setting. 
To test whether bone marrow can provide Fgfbp1-expressing (GFP positive) cells via the 
circulation to a healing wound, we isolated bone marrow cells from Fgfbp1+/gfp mice and 
transplanted those into WT mice with skin wounds (Fig. 6d). GFP fluorescence in the 
wounded area peaked at days two and three after wounding (Fig. 6e, f) and sections of 
the wounds showed strong GFP staining of cells in the granulation tissue (Fig. 6e, 
magnified in Fig. S9e). These transplant experiments demonstrate that Fgbp1-expressing 
cells home to the wound from both the circulation and adjacent tissue and reveal that 
Fgfbp1-expressing bone marrow-derived cells are recruited to healing wounds.  
 
Endogenous Fgfbp1 contributes to neoangiogenesis  
Subcutaneous matrigel plugs are a well-defined model of neoangiogenesis that mimics 
part of the wound healing process and is driven by the invasion of monocytic cells 
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recruited from the circulation (Anghelina et al. 2004). In earlier studies FGFBP1 was 
found expressed in tissue resident monocytes / macrophage (Ray et al. 2014) and gain-of-
function studies had shown that expression of FGFBP1 enhances neoangiogenesis in a 
matrigel plug model (Tassi et al. 2011). In Fgfbp1-KO mice, a significant 3-4-fold 
reduction of cells that fully invade the matrigel plug and reach the center was observed. It 
is noteworthy that similar numbers of infiltrating cells were observed at the edges of the 
plugs (regions 1 and 5; Fig. 6g, h). Examination of matrigel plugs in Fgfbp1+/gfp reporter 
mice revealed a strong GFP staining of the majority of invasive cells. A large percentage 
of the Fgfbp1-expressing cells were inflammatory cells with multilobular nuclei (Fig. 
S9f).  
 
Additional phenotypic analysis of FGFBP1-KO mice 
Fgfbp1-KO mice were viable and fertile and did not show any gross phenotypic 
abnormalities. The expected Mendelian ratio of the offspring indicated a lack of 
embryonic lethality in mice in contrast to chick embryonic development where FGFBP1 
is crucial for survival (Gibby et al. 2009). To detect subtle phenotypic changes, we 
subjected a cohort of WT and KO animals to a systematic and comprehensive 
characterization for 550 parameters that include behavior, neurology, morphology, 
metabolism, hematology and immunology (Fuchs et al. 2009). In summary of the 
analyses detailed in Tables S1 to S21, and Figs. S10 to S15, we found significant 
phenotypic alteration in KO mice in the ratio of fat versus lean body mass, food intake, 
spleen and heart weights, blood glucose, cholesterol, iron binding capacity, lactate, urea, 
serum IgG3 and IgE, behavioral tests, and in the auditory brain stem response.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
14 
 
Discussion  
Previous studies have shown that FGFBP1 interacts with FGF1 and 2 as well as with 
members of the FGF7 subfamily i.e. FGF7, 10 and 22 (Beer et al. 2005). These FGFs are 
expressed in the skin and signal through the IIIb isoform of FGFRs. Indeed, FGF22-
knockout mice develop fewer papilloma than WT mice during skin carcinogenesis while 
skin development and wound healing is not affected (Jarosz et al. 2012). Mice lacking 
keratinocyte Fgfr1b and Fgfr2b lose epidermal barrier function and the ability to maintain 
skin homeostasis (Yang et al. 2010). Also, a lack of Fgfr2b in keratinocytes made skin 
hypersensitive to papilloma formation (Grose et al. 2007). We have previously found that 
DMBA/TPA upregulates FGFBP1 in human skin grafted onto mice (Kurtz et al. 2004) 
and the analysis of published data shown above revealed increased FGFBP1 expression 
in hyperproliferative skin diseases such as psoriasis, actinic keratosis and SCC. 
Here we report that endogenous Fgfbp1 plays a significant role in skin repair and 
carcinogenesis. While Fgfbp1-KO mice did not show any gross phenotypic 
abnormalities, a functional screen showed a decrease of transepidermal waterloss 
(TEWL) in KO mice that matches with significant thickening of the epidermal layer in 
KO mice. Interestingly, keratinocyte-specific deletion of Fgfr1 and Fgfr2b resulted in 
changes of the barrier function and ulceration of mouse skin (Yang et al. 2010). 
Epidermal thickening was also observed in keratinocyte Fgfr2b-knockout skin (Grose et 
al. 2007). Taken together, the results show that FGFBP1 expression is induced upon 
injury and tissue regeneration, whilst loss of FGFBP1 slows the response to injury during 
the DMBA/TPA induced carcinogenesis, wound healing and invasion into a matrigel 
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plug. We found that the FGFR1c isoform is upregulated and the isoform ratio is shifted 
towards the mesenchymal c-isoform in the KO epidermis. This indicates that the loss of 
FGFBP1 causes an increase in mesenchymal expression pattern in the skin. This may 
contribute to the increased epithelial barrier function of KO skin and matches with the 
mesenchymal transition of the epidermis during carcinogenesis (Tanner and Grose 2015). 
We also noticed an increase of the macrophage marker F4/80 in KO epidermis, 
suggesting an increase in FGFR1c-expressing inflammatory cells in the epidermis. This 
influx could also contribute to a shift to a more mesenchymal expression pattern in KO 
epidermis. It is noteworthy that global gene expression changes in the skin of KO mice 
mimic the altered gene expression pattern observed after carcinogen treatment of WT 
skin. E.g. genes involved in epidermal development such as cytokeratins (Krt13, 16, 27, 
Sprr2d), immune response genes (Il6, Il17a, Il23, S100a8, S100a9) and the kallikrein 
peptidase, Klk6, are upregulated in the skin of KO mice. Indeed, these genes are 
upregulated in psoriasis (Kim et al. 2016; Schonthaler et al. 2013; Vinter et al. 2014) 
squamous cell carcinoma (De Heller-Milev et al. 2000; Ghosh et al. 2015; Iotzova-Weiss 
et al. 2015; Kishibe et al. 2007; Lessard and Coulombe 2012; Prassas et al. 2015; 
Reichelt et al. 2004) and in chronic wounds (Singh et al. 2016). Also, expression of the 
S100a8/a9 heterodimer which is thought to suppress papilloma formation (McNeill and 
Hogg 2014) is increased in the skin of KO mice (Fig. 4k). Overall the loss of Fgfbp1 
increases the pro-inflammatory gene expression in the skin.  
The deletion of FGF22 led to a delay in carcinogen-induced papilloma formation (Jarosz 
et al. 2012) matching with our results. Wound healing was, however, not affected in 
FGF22-KO mice. Also, it has been shown that lack of FGFR2b in keratinocytes leads to 
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increased and spontaneous papilloma formation suggesting that FGFR2b functions as a 
tumor suppressor in the skin (Grose et al. 2007). Our results are somewhat different since 
we observed a strong upregulation of the mesenchymal FGFR1c in the epidermis of KO 
mice. This might increase the mesenchymal character of the epidermis preventing 
hyperproliferation of the keratinocytes in the epidermal layer of the skin. Finally, 
vascular leakage in papilloma and wound granulation tissues in KO mice is reminiscent 
of vascular leakage after FGFBP1 knock-down in chicken embryos (Gibby et al. 2009).  
The Fgfbp1+/gfp reporter mice allowed us to distinguish between the contribution of 
locally resident and systemically recruited Fgfbp1-expressing cells. In the skin transplant 
experiments Fgfbp1-expressing cells migrate into healing wounds as indicated by GFP 
activity in the granulation tissue. Furthermore, the bone marrow transplant from 
Fgfbp1+/gfp reporter mice shows that these infiltrating cells originate from bone marrow 
and enter the wounds via the circulation. The model also demonstrates that Fgfbp1 is an 
indicator of differentiation of infiltrating cells. Early during wound healing infiltrating 
cells are derived from the hematopoetic lineage in the bone marrow but switch to 
mesenchymal progenitor cells during tissue remodeling (Opalenik and Davidson 2005). 
In our study, during the inflammatory phase of wound healing (day 4) most of the 
inflammatory cells express Fgfbp1. Similarly, in the neoangiogenesis matrigel assay the 
majority of invasive, inflammatory cells express Fgfbp1. This corroborates previous 
results by us and others that FGFBP1 is expressed in tissue-infiltrating monocytes / 
macrophage (Ray et al. 2014).  
In conclusion, our study identifies endogenous Fgfbp1 as a significant modulator of 
pathways that are involved in early carcinogenesis and inflammatory tissue regeneration 
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and links Fgfbp1 expression to tissue-infiltrating inflammatory cells from the bone 
marrow.  
 
Material and Methods 
 
Mice 
Mice were housed with food and water available ad libitum under standard laboratory 
conditions. For studies involving WT and KO mice, heterozygous breeder pairs were 
used and WT and KO littermates were selected for subsequent studies. Animals were 
separated based on sex, but not genotype. All animal studies were approved by 
Georgetown University’s institutional animal care and use committee and conducted 
according to the NIH Guide for the Care and Use of Laboratory Animals. 
 
Generation of knockout mice 
The Fgfbp1-knockout targeting vector, Fgfbp1-KO mice and Fgfbp1gfp mice in a 
C57BL/6 and SV129 mixed background were generated by Ingenious Targeting 
Company and is described in the Supplemental Materials.   
 
Transepidermal Water Loss (TEWL)  
Mouse skin was analyzed in a non-invasive manner with a special Tewameter 
(AquaFlux-AF200) that was placed on the skin. During a short time of 60 to 90 seconds 
TEWL [g/(m2h)] was recorded (Fluhr et al. 2006). 
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Illumina RNA expression assay and Ingenuity pathway analysis 
PolyA-RNA was analyzed by the UCLA Neuroscience Genomics core utilizing an 
Illumina bead array (Mouse-ref8-v.2.0) system. RNA expression values were evaluated 
with the Ingenuity Pathway analysis software.  
 
Separation of dermis from epidermis 
The epidermis dissociation kit (Miltenyi-Biotec) was used for epidermis/dermis 
separation according to manufacturer’s instructions. 
 
Statistical Analyses 
Prism5 (GraphPad) software was used to compare the means of two or more groups by 
Student’s t-test or analysis of variance, respectively. Statistical significance was defined 
as P < 0.05. Figures legends: *, P<0.05; **, P<0.01; ***, P<0.001 
An expanded Methods section is available in the Supplementary Materials and Methods. 
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Figure Legends: 
 
Figure 1: Generation of Fgfbp1 KO and GFP-knock-in mice. (a) Schematic of the 
knockout strategy for the Fgfbp1 gene depicts the endogenous locus of the Fgfbp1 gene 
on chromosome 5 and the targeting construct below. Mice with the targeted insertion of a 
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floxed Fgfbp1 Neo and Gfp cassette in the Fgfbp1 locus (Fgfbp1loxP-neo-gfp) were crossed 
with Cre expressing mice resulting in an insertion of a GFP reporter allele (Fgfbp1gfp), or 
with FLPase mice resulting in a floxed Fgfbp1 (Fgfbp1loxp) allele. Fgfbp1loxP mice were 
further crossed with cre-mice to generate Fgfbp1-KO mice (Fgfbp-/-, KO). Numbered 
arrows depict locations of genotyping primer (Suppl. Table S22). (b-f) PCR analysis of 
genomic DNA isolated from tail snips. (b) Primers 4 and 7 resulted in an amplicon of 
5000 bp only in the allele with the floxed Fgfbp1 Neo and GFP cassette. (c) Primers 1 
and 2 resulted in an amplicon of 478 bp with the 5’loxP site in the floxed Fgfbp1 allele 
and 416 bp in the WT allele. (d) Primers 3 and 6 resulted in an amplicon of 582 bp with 
the 3’loxP site in the floxed Fgfbp1 allele and 463 bp in the WT allele. (e) Primers 1 and 
5 resulted in an amplicon of 484 bp only in the GFP reporter allele. (f) Primers 1 and 6 
resulted in an amplicon of 432 bp in the KO allele and 2.5kb in the WT allele. 
 
Figure 2: Fgfbp1-KO mouse epidermis is thicker and has reduced permeability. 
(a,b) Representative high magnification pictures of Masson’s trichrome stained tissue 
section of skin from WT and KO mice shows a thicker epidermal layer (E) in KO mice. 
(b) In contrast to the epidermis, dermis, fat layer and muscle are not significantly 
different.  (Mann Whitney test, WT n=5; KO n=6; 20 fields per skin sample). (c) 
Proliferation of basal keratinocytes in KO epidermis is higher than in WT (PCNA 
positive nuclei, Student’s t test, n=5). (d) Nucleated keratinocyte layers in KO epidermis 
contain multiple strata whereas WT epidermis is mostly a monolayer (Chi-square test, 
n=3), (e) Representative images of skin section stained for Claudin 1, Filaggrin, PCNA 
(scale bar = 100 µm). (f) Transepidermal water loss (TEWL) was decreased in male KO 
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compared to WT males (Student’s t test, WT n=14; KO n=15). (g) RNA expression in 
separated dermis and epidermis (Student’s t test, WT n=4; KO n=3). 
 
Figure 3: Effect of topical Aldara treatment. (a) Daily treatment of shaved back skin 
of Fgfbp1gfp mice for 4 days. Skin turned red as the inflammation progresses. (b) 
Myeloperoxidase (MPO) activity (Student’s t-test, WT n=4; KO n=5). (c) Induction of 
Fgfbp1 expression in WT skin. (d) GFP fluorescence in Aldara and ctrl (vaseline) treated 
mice for 5 days. Fluorescence intensity is shown as scaled counts/s in a heatmap from 0 
(black) to 0.8 (dark red). (e) Quantification of GFP-fluorescence in panel b (Chi-square, 
n=2). (f) Masson’s trichrome stained tissue sections of WT and KO epidermis (scale bar 
= 50 µm). (g) Quantification of the thickness of the epidermis (Student’s t-test, n=7). (h) 
Effect on mRNA expression of Krt16, Il6, Il17a and Il23. (Student’s t test, n=7) 
 
Figure 4: DMBA/TPA (D/T) effects are delayed in Fgfbp1-KO mice. (a) Treatment 
scheme: A single topical treatment with DMBA was followed by biweekly TPA 
treatments for 180 days. (b) In vivo fluorescence of Fgfbp1+/gfp mouse skin after 180 days 
of treatment shows GFP activity in papillomas. Visible (left panel) and green 
fluorescence channels (right panel) are shown. Arrows indicate papillomas (scale bar = 5 
mm). (c) Immunostaining of representative tissue sections with anti-GFP antibody shows 
staining of the epidermis (E) excluding the basal layer of keratinocytes. (Dermis (D), 
scale bar =200 µm (top panel), 100 µm (bottom panel), magnified in Suppl. Fig. S5b), 
(d) GFP RNA expression in Fgfbp1+/gfp mice after 180 days of treatment (n=3). (e) The 
thickness of the epidermal layer progressively increased upon treatment. Biopsies were 
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taken and the epidermal thickness was measured. On days 57 and 124 only papilloma-
free skin sections were measured. (f) Papilloma on day 161. (g) Kaplan-Meier plot of 
papilloma occurrence (p<0.01; Mantel-Cox test, WT n=9; KO n=8). (h) Papilloma 
frequency (2-way ANOVA, WT n=9; KO n=8). (i) Vascular leakiness in papilloma 
indicated by extravasated erythrocytes (student’s t-test, n=5, 35 fields per sample). (j) 
Representative anti CD31-stained tissue section; E=epidermis, V=vessel; interrupted 
white line surrounds area with extravasated erythrocytes (scale bar = 100 µm). (k) 
Illumina bead array analysis of DMBA/TPA treated skin shows induction of Fgfbp1 (left 
panel) and increased expression of S100a8, Krt16, Sprr2d and Klk6. Baseline expression 
is higher in Fgfbp1-KO skin but induced upon DMBA/TPA treatment (Student’s t-test, 
WT n=4; KO n=3).  
 
Figure 5: Wound healing is delayed in Fgfbp1-KO mice. (a) The back skin of WT and 
KO mice was wounded on day 0 and wound sizes were measured daily for 7 days (scale 
bar = 5 mm). (b) Quantification of wound sizes (2-way Anova, WT n=20; KO n=12). (c) 
Activation of the Fgfbp1 expression during wound healing indicated by fluorescence in 
Fgfbp1+/gfp mouse skin. Heat map images are shown (scale bar = 2.5 mm). (d) GFP 
quantitation after wounding. GFP fluorescence peaks on day 4 (student’s t-test for each 
time point, n=10). (e) Immunostaining of representative tissue sections with anti-GFP 
antibody (scale bar = 1 mm, magnified scale bar 100 µm, higher magnification in Suppl. 
Fig. S8b). (f) Representative images of hematoxylin/eosin stained wounds (scale bar = 1 
mm), magnified sections show extravasated red blood cells (eR), single erythrocytes 
(arrow heads); (scale bar = 100 µm, granulation tissue (G), fat (F), scab (S), dermis (D), 
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muscle (M), hair follicles/glands (H), epidermis (E) (higher magnification in Suppl. Fig 
S8c). (g) Relative opening of wounds, calculated by the ratio between wound opening 
divided by wound diameter (distance between collagen-containing dermis times 100, 
n=5). (h) Quantification of extravasated erythrocytes (Student’s t test; WT n=5; KO n=6 
wounds; means of at least 10 fields per wound). (i) Quantification of microvessels and 
capillaries (Student’s t test, WT n=5; KO n=6 wounds; at least 10 fields per wound). 
 
Figure 6: Fgfbp1-expressing cells migrate into wounds. (a to c) Host Fgfbp1 
expressing cells enter wound in transplanted skin. (a) Time line (in days) and schematic 
of experiments. Skin from a WT mouse was transplanted onto the back of a Fgfbp1+/gfp 
mouse, wounded after 7 days and fluorescence monitored. (b) Left panels: Bright field 
images and GFP fluorescence during wound healing (scale bar = 5 mm). Right panels: 
Immunostaining of a representative tissue section with an anti-GFP antibody shows 
staining of inflammatory cells that entered transplanted skin wound (scale bar = 250 µm). 
(c) Quantification of GFP signal in intact and wounded skin transplant (2-way Anova, 
n=7). (d to f) Wound healing with concurrent bone marrow transplant from the 
Fgfbp1+/gfp reporter model. (d) Schematic of the experiment. (e) Bright field and GFP 
fluorescence images of wounds over 4 days (scale bar = 5 mm). Immunostaining of 
representative tissue sections with anti-GFP antibody confirmed GFP-positive cells in 
granulation tissue of the wound (Scale bars = 500 µm top right panel, 100 µm bottom 
right panel; higher magnification in Suppl. Fig. S9e). (f) Quantification of GFP activity; 
2-way Anova, n=8. (g) Matrigel plug neoangiogenesis assay. H&E stained tissue sections 
of subcutaneously injected matrigel after 7 days in WT and KO mice. Scale bar, 100 µm. 
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(h) Quantification of invasive cells per field in different regions of the matrigel. Regions 
1 and 5 represent the edges of the plugs, regions 2-4 the center; WT n=12; KO n=20. 
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